<p>儘管已經有了強勁的表現，<strong>RxSight, Inc.</strong>（納斯達克代碼：RXST）的股票仍在繼續上漲，過去三十天上漲了 28%。然而，三十天的漲幅並沒有改變長期股東在過去十二個月中股價下跌 64% 所帶來的損失。</p>
<p>儘管價格有了明顯反彈，但你可能仍然對 RxSight 的市銷率（P/S）為 3.8 倍感到無所謂，因為美國醫療設備行業的中位市銷率也接近 3.5 倍。然而，如果沒有合理的基礎，投資者可能會忽視一個明顯的機會或潛在的挫折。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>查看我們對 RxSight 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200"/></p>
<p>納斯達克 GM:RXST 市銷率與行業比較 2025 年 12 月 12 日</p>
<h3>RxSight 最近的表現如何？</h3>
<p>RxSight 最近的收入增長與大多數其他公司相似。似乎許多人預計這種平庸的收入表現將持續下去，這使得市銷率受到抑制。如果你喜歡這家公司，你會希望這種情況至少能夠維持，以便在它還不太受歡迎時買入一些股票。</p>
<p>想要了解分析師對公司的估計的完整情況嗎？那麼我們 <strong>免費的</strong>RxSight 報告將幫助你揭示未來的趨勢。</p>
<h2>收入預測與市銷率是否匹配？</h2>
<p>RxSight 的市銷率對於一家僅預計實現適度增長的公司來説是典型的，重要的是，它的表現與行業保持一致。</p>
<p>回顧一下，我們看到公司去年成功實現了 11% 的收入增長。最近三年期間，收入整體增長了 244%，在一定程度上得益於其短期表現。因此，可以公平地説，最近的收入增長對公司來説是非常出色的。</p>
<p>展望未來，根據跟蹤該公司的十位分析師的預測，收入預計在未來三年內每年增長 3.3%。而行業預計每年將實現 136% 的增長，公司面臨較弱的收入結果。</p>
<p>考慮到這一點，我們發現 RxSight 的市銷率與其行業同行密切匹配令人感興趣。似乎大多數投資者忽視了相對有限的增長預期，並願意為接觸該股票而支付更高的價格。如果市銷率降至與增長前景更一致的水平，這些股東可能會為未來的失望埋下伏筆。</p>
<h2>關鍵結論</h2>
<p>RxSight 似乎重新受到關注，價格的顯著上漲使其市銷率迴歸到行業其他公司的水平。然而，僅僅依靠市銷率來判斷是否應該出售你的股票並不明智，但它可以作為公司未來前景的實用指南。</p>
<p>我們對分析師對 RxSight 收入前景的預測的分析顯示，其較差的收入前景並沒有像我們預期的那樣對其市銷率產生負面影響。目前，我們對市銷率並不樂觀，因為預測的未來收入不太可能長期支持更積極的情緒。需要積極的變化來證明當前的市銷率是合理的。</p>
<p>還有其他重要的風險因素需要考慮，我們發現 <strong>RxSight 有 2 個警告信號</strong>（其中 1 個讓我們有些不安！），在這裏投資之前你應該瞭解這些。</p>
<p>當然，<strong>有着良好盈利增長曆史的盈利公司通常是更安全的投資</strong>。所以你可能希望查看這份 <strong>免費的</strong> 其他公司集合，這些公司有合理的市盈率並且盈利增長強勁。</p>
<p>國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是人形的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

RXST

<p>RxSight, Inc.（納斯達克代碼：RXST）在過去 30 天內股價上漲了 28%，儘管過去一年股價下跌了 64%。該公司的市銷率為 3.8 倍，與行業平均水平相符，但預計年收入增長將温和，僅為 3.3%，而行業平均為 136%。如果增長未能證明當前的市銷率，投資者可能會感到失望。分析師建議謹慎行事，因為增長預期有限且存在潛在風險因素</p>

<p>Despite an already strong run, <strong>RxSight, Inc.</strong> (NASDAQ:RXST) shares have been powering on, with a gain of 28% in the last thirty days. Still, the 30-day jump doesn't change the fact that longer term shareholders have seen their stock decimated by the 64% share price drop in the last twelve months.</p>
<div class="lb-trans"><p>儘管已經有了強勁的表現，<strong>RxSight, Inc.</strong>（納斯達克代碼：RXST）的股票仍在繼續上漲，過去三十天上漲了 28%。然而，三十天的漲幅並沒有改變長期股東在過去十二個月中股價下跌 64% 所帶來的損失。</p>
</div><p>In spite of the firm bounce in price, you could still be forgiven for feeling indifferent about RxSight's P/S ratio of 3.8x, since the median price-to-sales (or &#34;P/S&#34;) ratio for the Medical Equipment industry in the United States is also close to 3.5x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.</p>
<div class="lb-trans"><p>儘管價格有了明顯反彈，但你可能仍然對 RxSight 的市銷率（P/S）為 3.8 倍感到無所謂，因為美國醫療設備行業的中位市銷率也接近 3.5 倍。然而，如果沒有合理的基礎，投資者可能會忽視一個明顯的機會或潛在的挫折。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行工作。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>See our latest analysis for RxSight</p>
<div class="lb-trans"><p>查看我們對 RxSight 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200" alt="" original-src="https://images.simplywall.st/asset/chart/62603649-ps-multiple-vs-industry-1-dark-2/1765536930200"/></p>
<p>NasdaqGM:RXST Price to Sales Ratio vs Industry December 12th 2025</p>
<div class="lb-trans"><p>納斯達克 GM:RXST 市銷率與行業比較 2025 年 12 月 12 日</p>
</div><h3>How Has RxSight Performed Recently?</h3>
<div class="lb-trans"><h3>RxSight 最近的表現如何？</h3>
</div><p>RxSight's revenue growth of late has been pretty similar to most other companies. It seems that many are expecting the mediocre revenue performance to persist, which has held the P/S ratio back. If you like the company, you'd be hoping this can at least be maintained so that you could pick up some stock while it's not quite in favour.</p>
<div class="lb-trans"><p>RxSight 最近的收入增長與大多數其他公司相似。似乎許多人預計這種平庸的收入表現將持續下去，這使得市銷率受到抑制。如果你喜歡這家公司，你會希望這種情況至少能夠維持，以便在它還不太受歡迎時買入一些股票。</p>
</div><p>Want the full picture on analyst estimates for the company? Then our <strong>free</strong> report on RxSight will help you uncover what's on the horizon.</p>
<div class="lb-trans"><p>想要了解分析師對公司的估計的完整情況嗎？那麼我們 <strong>免費的</strong>RxSight 報告將幫助你揭示未來的趨勢。</p>
</div><h2>Do Revenue Forecasts Match The P/S Ratio?</h2>
<div class="lb-trans"><h2>收入預測與市銷率是否匹配？</h2>
</div><p>RxSight's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.</p>
<div class="lb-trans"><p>RxSight 的市銷率對於一家僅預計實現適度增長的公司來説是典型的，重要的是，它的表現與行業保持一致。</p>
</div><p>Taking a look back first, we see that the company managed to grow revenues by a handy 11% last year. The latest three year period has also seen an excellent 244% overall rise in revenue, aided somewhat by its short-term performance. Therefore, it's fair to say the revenue growth recently has been superb for the company.</p>
<div class="lb-trans"><p>回顧一下，我們看到公司去年成功實現了 11% 的收入增長。最近三年期間，收入整體增長了 244%，在一定程度上得益於其短期表現。因此，可以公平地説，最近的收入增長對公司來説是非常出色的。</p>
</div><p>Looking ahead now, revenue is anticipated to climb by 3.3% per year during the coming three years according to the ten analysts following the company. With the industry predicted to deliver 136% growth each year, the company is positioned for a weaker revenue result.</p>
<div class="lb-trans"><p>展望未來，根據跟蹤該公司的十位分析師的預測，收入預計在未來三年內每年增長 3.3%。而行業預計每年將實現 136% 的增長，公司面臨較弱的收入結果。</p>
</div><p>With this in mind, we find it intriguing that RxSight's P/S is closely matching its industry peers. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.</p>
<div class="lb-trans"><p>考慮到這一點，我們發現 RxSight 的市銷率與其行業同行密切匹配令人感興趣。似乎大多數投資者忽視了相對有限的增長預期，並願意為接觸該股票而支付更高的價格。如果市銷率降至與增長前景更一致的水平，這些股東可能會為未來的失望埋下伏筆。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>關鍵結論</h2>
</div><p>RxSight appears to be back in favour with a solid price jump bringing its P/S back in line with other companies in the industry Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>RxSight 似乎重新受到關注，價格的顯著上漲使其市銷率迴歸到行業其他公司的水平。然而，僅僅依靠市銷率來判斷是否應該出售你的股票並不明智，但它可以作為公司未來前景的實用指南。</p>
</div><p>Our look at the analysts forecasts of RxSight's revenue prospects has shown that its inferior revenue outlook isn't negatively impacting its P/S as much as we would have predicted. At present, we aren't confident in the P/S as the predicted future revenues aren't likely to support a more positive sentiment for long. A positive change is needed in order to justify the current price-to-sales ratio.</p>
<div class="lb-trans"><p>我們對分析師對 RxSight 收入前景的預測的分析顯示，其較差的收入前景並沒有像我們預期的那樣對其市銷率產生負面影響。目前，我們對市銷率並不樂觀，因為預測的未來收入不太可能長期支持更積極的情緒。需要積極的變化來證明當前的市銷率是合理的。</p>
</div><p>There are also other vital risk factors to consider and we've discovered <strong>2 warning signs for RxSight</strong> (1 makes us a bit uncomfortable!) that you should be aware of before investing here.</p>
<div class="lb-trans"><p>還有其他重要的風險因素需要考慮，我們發現 <strong>RxSight 有 2 個警告信號</strong>（其中 1 個讓我們有些不安！），在這裏投資之前你應該瞭解這些。</p>
</div><p>Of course, <strong>profitable companies with a history of great earnings growth are generally safer bets</strong>. So you may wish to see this <strong>free</strong> collection of other companies that have reasonable P/E ratios and have grown earnings strongly.</p>
<div class="lb-trans"><p>當然，<strong>有着良好盈利增長曆史的盈利公司通常是更安全的投資</strong>。所以你可能希望查看這份 <strong>免費的</strong> 其他公司集合，這些公司有合理的市盈率並且盈利增長強勁。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是人形的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

RxSight, Inc.（納斯達克股票代碼：RXST）28% 的股價上漲與其收入不相符